Seegene Inc

Chart & Performance

D1W1MN

P/E

1,685.67

P/S

3.07

EPS

14.09

Div Yield, %

3.38%

Shrs. gr., 5y

-1.93%

Rev. gr., 5y

29.14%

Revenues

367.38b

-56.96%

Net income

669m

-99.63%

CFO

94.93b

-70.24%

Dividend

Sep 27, 2024200 KRW/sh

Earnings

Feb 14, 2025

Profile

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of six SNPs in factor II, factor V, and MTHFR genes; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy, H&E slides, and paraffin-embedded tissues; Apolipoprotein E genotypes; and BCR/ABL fusion gene from blood and whole bone marrow. In addition, it offers PCR machines; vial cap management systems; nucleic acid extraction systems; automated liquid handling workstations from nucleic acid extraction to PCR setup; and real-time PCR detection systems. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

URL

https://www.seegene.com/

IPO date

Sep 10, 2010

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	367,375,049 -56.96%	853,561,091 -37.73%	1,370,833,012 21.83%
Cost of revenue	325,513,957	570,592,101	488,735,292
Unusual Expense (Income)
NOPBT	41,861,092	282,968,991	882,097,720
NOPBT Margin	11.39%	33.15%	64.35%
Operating Taxes	(2,146,624)	43,127,067	151,595,622
Tax Rate		15.24%	17.19%
NOPAT	44,007,715	239,841,924	730,502,098
Net income	669,012 -99.63%	182,138,621 -66.05%	536,558,868 6.82%
Dividends	(38,075,665)	(51,111,567)	(70,019,475)
Dividend yield	3.53%	3.70%	2.22%
Proceeds from repurchase of equity	(89,875,605)	(70,408,409)	(29,613,292)
BB yield	8.32%	5.10%	0.94%
Debt
Debt current	94,559,588	100,721,154	56,261,234
Long-term debt	111,678,788	58,464,245	102,805,896
Deferred revenue	294,100	56,295,852
Other long-term liabilities	11,320,213	11,405,074	76,202,122
Net debt	(391,300,988)	(522,076,804)	(384,765,203)
Cash flow
Cash from operating activities	94,932,061	319,008,874	334,024,477
CAPEX	(25,153,769)	(72,451,621)	(66,111,766)
Cash from investing activities	(278,326,845)	(103,980,105)	(102,673,011)
Cash from financing activities	(156,700,106)	(144,501,126)	(110,302,439)
FCF	105,545,395	341,256,590	403,714,293
Balance
Cash	520,842,026	603,776,324	473,454,436
Long term investments	76,697,339	77,485,879	70,377,896
Excess cash	579,170,612	638,584,148	475,290,682
Stockholders' equity	1,152,736,750	1,198,627,916	1,056,096,266
Invested Capital	604,606,554	678,100,362	686,504,794
ROIC	6.86%	35.15%	151.48%
ROCE	3.54%	21.48%	75.93%
EV
Common stock shares outstanding	47,147	50,788	51,797
Price	22,900.00 -15.81%	27,200.00 -55.41%	61,000.00 -36.79%
Market cap	1,079,673,926 -21.84%	1,381,420,898 -56.28%	3,159,643,535 -37.01%
EV	691,071,062	861,851,652	2,777,068,650
EBITDA	107,525,888	340,892,253	918,356,273
EV/EBITDA	6.43	2.53	3.02
Interest	6,219,428	5,445,177	3,774,894
Interest/NOPBT	14.86%	1.92%	0.43%